Results for tag: "Short Bowel Syndrome Drug"

Short Bowel Syndrome (SBS) is a rare disorder that affects the small intestine, resulting in malabsorption of nutrients and fluids. It is typically caused by the surgical removal of a large portion of the small intestine, or by a congenital defect. Treatment for SBS typically involves the use of specialized drugs to help the body absorb nutrients and fluids, as well as to reduce the risk of infection. The SBS drug market is a subset of the larger gastrointestinal drug market, which includes drugs used to treat a variety of gastrointestinal disorders. The SBS drug market is relatively small, but is expected to grow in the coming years due to increasing awareness of the disorder and the development of new treatments. Some of the major companies in the SBS drug market include AbbVie, Allergan, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Takeda. Show Less Read more